Seeneuro Medical, a China-based innovative neuromodulation company, will continue to target its product lines in the field of neuromodulation with the fresh proceeds.
Seeneuro Medical (Chinese: 神络医疗) announced its completion of the Series B round of financing worth nearly CNY 100 million recently. The round was led by SDIC Unity Capital (Chinese: 国投创合), with the participation from the existing investor BioTrack Capital (Chinese: 博远资本).
The funds will be used for new product development, clinical studies, registration applications and chip iterations. Seeneuro Medical has completed three financing rounds of over CNY 100 million in the past year. The continuous recognition by professional investment institutions shows the great potential of the neuromodulation track and validates the value of the company and its solutions.
Founded in 2018, Seeneuro Medical focuses on the independent development and production of medical devices in implantable neuromodulation. With the mission to continuously provide more advanced and effective treatments for doctors and patients, the company is dedicated to improving the quality of life for patients with refractory diseases.
Seeneuro Medical is developing neuromodulation products with different technical paths and application scenarios, and each direction is well underway. Spinal Cord Stimulation (SCS) is one of the company's core products. Peripheral Nerve Stimulation (PNS) is a temporary, short-term peripheral nerve neuromodulation system developed by the company for acute and chronic pain relief. In the future, Seeneuro Medical will continue to expand its product lines for pain, urinary incontinence, heart failure, hypertension, apnea and other diseases.
The company's competitors include Neulive Medical (Chinese: 神畅医疗), PINS Medical (Chinese: 品驰医疗) and Leadinno Medical Valley (Chinese: 领创医谷).